These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 22894676)
1. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. Imarisio I; Paglino C; Ganini C; Magnani L; Caccialanza R; Porta C Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676 [TBL] [Abstract][Full Text] [Related]
2. [Use of sorafenib in patients with hepatocellular or renal carcinoma]. Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452 [TBL] [Abstract][Full Text] [Related]
3. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708 [TBL] [Abstract][Full Text] [Related]
4. Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience. Scandurra G; Aiello RA; Alì M; Taibi E; Sanò MV; Todaro FM; La Rocca R; Licciardello P; Caruso M Future Oncol; 2012 May; 8(5):609-15. PubMed ID: 22646774 [TBL] [Abstract][Full Text] [Related]
5. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Iavarone M; Cabibbo G; Piscaglia F; Zavaglia C; Grieco A; Villa E; Cammà C; Colombo M; Hepatology; 2011 Dec; 54(6):2055-63. PubMed ID: 21898496 [TBL] [Abstract][Full Text] [Related]
6. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma. Richards TM; Plowman PN; Reznek R; Ball SA Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217 [No Abstract] [Full Text] [Related]
7. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536 [TBL] [Abstract][Full Text] [Related]
8. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953 [TBL] [Abstract][Full Text] [Related]
9. Sorafenib in hepatocellular carcinoma. Josephs DH; Ross PJ Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. Welker MW; Lubomierski N; Gog C; Herrmann E; Engels K; Vogl TJ; Bechstein WO; Zeuzem S; Trojan J J Chemother; 2010 Jun; 22(3):205-11. PubMed ID: 20566428 [TBL] [Abstract][Full Text] [Related]
12. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma]. Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424 [TBL] [Abstract][Full Text] [Related]
13. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]. Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505 [No Abstract] [Full Text] [Related]
14. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337 [TBL] [Abstract][Full Text] [Related]
17. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Kim R; Byrne MT; Tan A; Aucejo F Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937 [TBL] [Abstract][Full Text] [Related]
19. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib]. Xie XD; Piao Y; Liu ZZ Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872 [No Abstract] [Full Text] [Related]
20. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P Digestion; 2011; 83(4):275-82. PubMed ID: 21282952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]